Wednesday, January 28, 2026 at 5:00 p.m. ET. CALL PARTICIPANTS. Chief Executive Officer — William J. Lansing. Chief Financial Officer — St ...
The authors, Dr. Gong et al, concluded that Q-1802 plus XELOX has manageable safety and promising antitumor activity as first-line therapy for CLDN18.2-positive/HER2-negative advanced GC/GEJ, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results